Tsukuda M
Gan To Kagaku Ryoho. 1984 Nov;11(11):2335-41.
Clinical effects of aclacinomycin-A (ACM) were evaluated in 30 patients with head and neck carcinoma. ACM was continuously administered intravenously at a dose of 20 mg/body for 4 days. After 2 weeks cessation the same courses were repeated. The maximum cumulative dose was 400 mg. Overall objective response rate was 53.3% for head and neck carcinoma, but, the effective rates were different according to histopathological classification of carcinoma. The most responsive tumor was adenocarcinoma. With squamous cell carcinoma the response rate was correlated with the degree of differentiation. Namely, 88.9% of anaplastic squamous cell carcinoma cases responded while the effective rate was only 14.3% for well and moderately differentiated types. In the evaluation of side effects, myelosuppresive toxicity, one of the dose-limiting factors in ACN trials, was slight using in this administration method. Also, any changes in electrocardiograms, occurring during ACM administration, were reversible and negligible. Manifestations of side effects with systemic ACM administration appeared to be less pronounced than those of adriamycin.
对30例头颈部癌患者评估了阿克拉霉素-A（ACM）的临床疗效。ACM以20mg/体的剂量连续静脉给药4天。停药2周后重复相同疗程。最大累积剂量为400mg。头颈部癌的总体客观缓解率为53.3%，但根据癌的组织病理学分类，有效率有所不同。反应最明显的肿瘤是腺癌。对于鳞状细胞癌，缓解率与分化程度相关。即，未分化鳞状细胞癌病例的缓解率为88.9%，而高分化和中分化类型的有效率仅为14.3%。在副作用评估中，ACN试验中的剂量限制因素之一骨髓抑制毒性，在这种给药方法中很轻微。此外，ACM给药期间出现的任何心电图变化都是可逆的且可忽略不计。全身给予ACM的副作用表现似乎比阿霉素的副作用表现轻。
